RT Generic
T1 Beta-blockers and COPD: the show must go on.
A1 Lopez-Campos, Jose Luis
A1 Marquez-Martin, Eduardo
A1 Casanova, Ciro
K1 Adrenergic Agents
K1 Clinical Relevance
K1 Cardiovascular Diseases
K1 Heart
AB Identification of comorbidities is now recognised as one of the pillars for a comprehensive clinical evaluation in chronic obstructive pulmonary disease (COPD) [1]. Specifically, the burden of coexisting cardiovascular disease in COPD has gained significant attention, with specific algorithms being developed for its clinical detection [2]. The relationship between the heart and COPD is of clinical relevance not only for the well-documented relationship between the two organs [3], but also for the potential mutual influence of treatments. The interactions between oral beta-blockers and inhaled β-adrenergic drugs pose significant challenges for clinicians involved in the management of patients with chronic cardiorespiratory conditions. In particular, the use of beta-blockers in COPD remains the subject of ongoing controversy
PB European Respiratory Society
YR 2016
FD 2016-08-31
LK http://hdl.handle.net/10668/10406
UL http://hdl.handle.net/10668/10406
LA en
NO Lopez-Campos JL, Márquez-Martín E, Casanova C. Beta-blockers and COPD: the show must go on. Eur Respir J. 2016 Sep;48(3):600-3.
DS RISalud
RD Apr 11, 2025